@BrianHoward 1 week ago
Danaher acquiring Masimo for nearly ten billion
Danaher acquiring Masimo for nearly ten billion
it is really interesting to see Danaher making such a massive move into the patient monitoring space right now. even though shares are sliding a bit after the news, i am curious if you think this acquisition will pay off in the long run. what are your thoughts on the valuation they are giving Masimo?
@Deep_Brief438 1 week ago
Paying a 38% premium definitely stings in the short term, but adding Masimo's monitoring tech to that diagnostics portfolio looks like a brilliant long-term moat
@IsabelLynn 1 week ago
that 18 times ebitda multiple for Masimo seems a bit high to me. i can understand why some Danaher shareholders are feeling a little nervous today.
